


PE anti-mouse CD304 (Neuropilin-1)


Catalog # / Size:	1326015 / 25 µg 1326020 / 100 µg
Clone:	3E12
Isotype:	Rat IgG2a, κ
Immunogen:	Extracellular region of mouse CD304
Reactivity:	Mouse
Preparation:	The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration:	NULL



C57BL/6 mouse splenocytes were stained with CD4 APC and CD304 (clone 3E12) PE (top) or rat IgG2a, κ PE isotype control (bottom).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.



Application References:	1. Blankenhaus B, <i>et al.</i> 2014. <i>PLoS Pathog.</i> 10:1003913. PubMed 2. Verhagen J and Wraith DC. 2014. <i>J. Immunol. Methods.</i> S0022. (FC) PubMed 3. Verhagen J, <i>et al.</i> 2014. <i>PLoS One.</i> 9e:108023. (FC) PubMed
--------------------------------	---

Description:	CD304, also known as neuropilin-1, is a 140 kD type I transmembrane protein. Its extracellular region contains two CUB, two FV/FVIII, and one MAM domain. It is expressed by natural regulatory T cells (nTreg), a subset of invariant natural killer T cells (iNKT), endothelial cells, and neurons. Neuropilin-1 stabilizes the interaction between Tregs and dendritic cells, contributes to the recruitment of tumor-infiltrating Tregs in response to tumor-derived VEGF, and influences the process of angiogenesis and axon guidance. The ligands of CD304 are VEGF165 and semaphorin-3A.
Antigen References:	1. Yadav M, <i>et al.</i> 2012. <i>J. Exp. Med.</i> 209:1713. 2. Weiss JM, <i>et al.</i> 2012. <i>J. Exp. Med.</i> 209:1723. 3. Hansen W, <i>et al.</i> 2012. <i>J. Exp. Med.</i> 209:2001. 4. Milpied P, <i>et al.</i> 2011